Abstract
Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily and form heterodimers with retinoid X receptor. To date, three PPARs isoforms have been isolated and termed α, β (or δ), and γ. Although PPARγ is expressed predominantly in adipose tissue and associated with adipocyte differentiation and glucose homeostasis, it has been recently demonstrated that PPARγ is present in a variety of cell types. Synthetic antidiabetic thiazolidinediones (TZDs) and natural prostaglandin D2 (PGD2) metabolite, 15-deoxy-Δ12, 14- prostaglandin J2 (15d-PGJ2), are well-known as ligands for PPARγ. After it has been reported that activation of PPARg suppresses production of proinflammatory cytokines in activated macrophages, medical interest in PPARg have grown and a huge research effort has been concentrated. PPARg, is currently known to be implicated in various human chronic diseases such as diabetes mellitus, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, and Alzheimers disease. Moreover, PPARγ ligands have potent tumor modulatory effects against colorectal, prostate, and breast cancers. Recent studies suggest that TZDs not only ameliorate insulin sensitivity but also have pleiotropic effects on many tissues and cell types. Although activation of PPARγ seems to have beneficial effects on atherosclerosis and heart failure, the mechanisms by which PPARγ ligands prevent the development of cardiovascular diseases are not fully understood. This review will focus on the latest developments in the PPARγ field and the roles of PPARg-dependent pathway in cardiovascular diseases.
Keywords: atherosclerosis, cardiac hypertrophy, glitazones, heart failure, myocardial infarction, th1/th2, thiazolidinedione
Current Pharmaceutical Design
Title: Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Volume: 10 Issue: 22
Author(s): Hiroyuki Takano, Hiroshi Hasegawa, Yunzeng Zou and Issei Komuro
Affiliation:
Keywords: atherosclerosis, cardiac hypertrophy, glitazones, heart failure, myocardial infarction, th1/th2, thiazolidinedione
Abstract: Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily and form heterodimers with retinoid X receptor. To date, three PPARs isoforms have been isolated and termed α, β (or δ), and γ. Although PPARγ is expressed predominantly in adipose tissue and associated with adipocyte differentiation and glucose homeostasis, it has been recently demonstrated that PPARγ is present in a variety of cell types. Synthetic antidiabetic thiazolidinediones (TZDs) and natural prostaglandin D2 (PGD2) metabolite, 15-deoxy-Δ12, 14- prostaglandin J2 (15d-PGJ2), are well-known as ligands for PPARγ. After it has been reported that activation of PPARg suppresses production of proinflammatory cytokines in activated macrophages, medical interest in PPARg have grown and a huge research effort has been concentrated. PPARg, is currently known to be implicated in various human chronic diseases such as diabetes mellitus, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, and Alzheimers disease. Moreover, PPARγ ligands have potent tumor modulatory effects against colorectal, prostate, and breast cancers. Recent studies suggest that TZDs not only ameliorate insulin sensitivity but also have pleiotropic effects on many tissues and cell types. Although activation of PPARγ seems to have beneficial effects on atherosclerosis and heart failure, the mechanisms by which PPARγ ligands prevent the development of cardiovascular diseases are not fully understood. This review will focus on the latest developments in the PPARγ field and the roles of PPARg-dependent pathway in cardiovascular diseases.
Export Options
About this article
Cite this article as:
Takano Hiroyuki, Hasegawa Hiroshi, Zou Yunzeng and Komuro Issei, Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases, Current Pharmaceutical Design 2004; 10 (22) . https://dx.doi.org/10.2174/1381612043383719
DOI https://dx.doi.org/10.2174/1381612043383719 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters 15-Deoxy-Δ 12,14-Prostaglandin J2 Exerts Pro- and Anti-Inflammatory Effects in Mesangial Cells in a Concentration-Dependent Manner
Inflammation & Allergy - Drug Targets (Discontinued) From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry FBP1, A Tumor Suppressor and Negative Regulator of Glycolysis, was Epigenetically Silenced in Pancreatic Cancer
Current Signal Transduction Therapy Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics Development of Thieno[3`,2`:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide Derivatives as the Estrogen Receptor Ligands: Synthesis, Characterization and Biological Activity
Medicinal Chemistry Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Current Molecular Pharmacology Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
Combinatorial Chemistry & High Throughput Screening DNA Fragmentation, Cell Cycle Arrest, and Docking Study of Novel Bis Spiro-cyclic 2-oxindole of Pyrimido[4,5-b]quinoline-4,6-dione Derivatives Against Breast Carcinoma
Current Cancer Drug Targets Withdrawal Notice: Computational Druglikeness Assessment, Synthesis, Characterization and In vitro Biological Activity Evaluation of some Novel Mixed Metal Complexes of 2-(butan-2-ylidene) Hydrazinecarbothioamide
Combinatorial Chemistry & High Throughput Screening Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Andrographolide Inhibits Proliferation of Colon Cancer SW-480 Cells <i>via</i> Downregulating Notch Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Updated Research and Applications of Small Molecule Inhibitors of Keap1-Nrf2 Protein-Protein Interaction: a Review
Current Medicinal Chemistry